Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Leukemia

• Publication date

  2019-08-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41375-019-0537-2PMID 31462732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

  2016cited by this paper
• Multiple myeloma

  2015cited by this paper
• Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival

  2015cited by this paper
• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

  2014cited by this paper
• Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

  2014cited by this paper
• Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

  2013cited by this paper
• Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

  2013cited by this paper
• Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry.

  2013cited by this paper
• Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

  2012cited by this paper
• Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.

  2012cited by this paper
• Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

  2012cited by this paper
• Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.

  2012cited by this paper
• Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

  2012cited by this paper
• Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

  2012cited by this paper
• Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

  2011cited by this paper
• Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

  2011cited by this paper
• Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

  2010cited by this paper
• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  2009cited by this paper
• A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.

  2008cited by this paper
• A comparison of allografting with autografting for newly diagnosed myeloma.

  2007cited by this paper
• Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

  2006cited by this paper
• Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple

  2005cited by this paper
• Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma

  2005cited by this paper
• Single versus double autologous stem-cell transplantation for multiple myeloma.

  2003cited by this paper
• Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.

  2002cited by this paper
• Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

  2001cited by this paper
• Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.

  2000cited by this paper
• Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin’s lymphomas and Hodgkin’s disease

  1999cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996cited by this paper

• EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

  2025cites this paper
• Multiples Myelom: Erstlinientherapie des multiplen Myeloms - Neue Therapiekonzepte und kürzlich ­zugelassene Optionen

  2025cites this paper
• Tandem autologous hematopoietic stem cell transplantation in multiple myeloma: A historical perspective and current challenges

  2025influential citation
• Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years

  2024cites this paper
• Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible

  2024cites this paper
• Clinical Characteristics, Cytogenetic Risks, and Prognoses of Young Multiple Myeloma Patients in the Era of Novel Therapies

  2024cites this paper
• NOVEL DRUG COMBINATIONS AND DONOR LYMPHOCYTE INFUSIONS ALLOW PROLONGED DISEASE CONTROL IN MULTIPLE MYELOMA PATIENTS RELAPSING AFTER ALLOGENEIC TRANSPLANT: New treatments for Multiple Myeloma patients relapsing after Allo transplant.

  2024cites this paper
• Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis

  2023influential citation
• Experts’ consensus on the definition and management of high risk multiple myeloma

  2023cites this paper
• Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study.

  2023cites this paper
• Autologous and Allogeneic Stem Cell Transplantation as Salvage Treatment Options for Relapsed/Refractory Multiple Myeloma: A Single-center Experience over 20 Years

  2022cites this paper
• How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma

  2022cites this paper
• Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients

  2022cites this paper
• Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions

  2022cites this paper
• Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma

  2022influential citation
• Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma

  2021cites this paper
• Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups

  2021cites this paper
• Role of Stem Cell Transplantation in Multiple Myeloma

  2021cites this paper
• Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high‐risk myeloma patients – a single centre experience

  2021cites this paper
• Current approaches to management of high‐risk multiple myeloma

  2021cites this paper
• Immunomodulators in newly diagnosed multiple myeloma: current and future concepts

  2021cites this paper
• Long-term outcome after allogeneic stem cell transplantation in multiple myeloma

  2021cites this paper
• How I Treat High-risk Multiple Myeloma.

  2021cites this paper
• Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study

  2021cites this paper
• Allogeneic Stem Cell Transplantation in Multiple Myeloma

  2021cites this paper
• Summary of the Third Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

  2020cites this paper
• Recommendations on the management of multiple myeloma in 2020

  2020cites this paper
• Clinical characteristics of testicular extramedullary involvement in multiple myeloma

  2020cites this paper
• Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure

  2020cites this paper
• Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?

  2020cites this paper
• Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT

  2020cites this paper
• Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?

  2020cites this paper
• Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma

  2020cites this paper
• Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

  2020cites this paper
• Multiples Myelom – dynamische Entwicklungen in Krankheitsverständnis und Therapie

  2020cites this paper
• Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma.

  2020cites this paper
• Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT

  2020cites this paper
• Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

  2019cites this paper